Last reviewed · How we verify
DLBCL arising from follicular lymphoma
Approved treatments
- Kymriah · Novartis Pharmaceuticals Corporation
Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- DLBCL arising from follicular lymphoma patent landscape — cliff calendar, originator estates, attackable patents
- DLBCL arising from follicular lymphoma treatment landscape brief
- DLBCL arising from follicular lymphoma treatment updates RSS
Frequently asked questions about DLBCL arising from follicular lymphoma
What drugs treat DLBCL arising from follicular lymphoma?
Tracked treatments include Kymriah.
What is the treatment for DLBCL arising from follicular lymphoma?
Standard treatment for DLBCL arising from follicular lymphoma includes Kymriah. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: DLBCL arising from follicular lymphoma patent cliff · DLBCL arising from follicular lymphoma CI report
- Treatment: Kymriah · Novartis Pharmaceuticals Corporation
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing